XML 36 R21.htm IDEA: XBRL DOCUMENT
v3.22.4

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION | 12 Months Ended
--- | ---
Dec. 31, 2022
Risks and Uncertainties [Abstract] |
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION | REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION The following table presents Total Revenues and disaggregates Net Product Revenues by product.
| Years Ended December 31,
| 2022 |  | 2021 |  | 2020
Net product revenues by product: |  |  |  |  |
VIMIZIM | $ | 663,739 |  |  | $ | 623,145 |  |  | $ | 544,257 |
NAGLAZYME | 443,794 |  |  | 380,449 |  |  | 391,298 |
PALYNZIQ | 255,032 |  |  | 237,474 |  |  | 170,983 |
KUVAN | 227,577 |  |  | 285,776 |  |  | 457,736 |
VOXZOGO | 169,128 |  |  | 5,855 |  |  | — |
BRINEURA | 154,333 |  |  | 128,034 |  |  | 110,192 |
FIRDAPSE | — |  |  | — |  |  | 1,288 |
Total net product revenues marketed by the Company | 1,913,603 |  |  | 1,660,733 |  |  | 1,675,754 |
ALDURAZYME net product revenues marketed by Sanofi | 128,422 |  |  | 122,765 |  |  | 130,107 |
Total net product revenues | 2,042,025 |  |  | 1,783,498 |  |  | 1,805,861 |
Royalty and other revenues | 54,014 |  |  | 62,777 |  |  | 54,594 |
Total revenues | $ | 2,096,039 |  |  | $ | 1,846,275 |  |  | $ | 1,860,455 |
The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide.
| Years Ended December 31,
| 2022 |  | 2021 |  | 2020
United States | $ | 684,284 |  |  | $ | 657,700 |  |  | $ | 756,863 |
Europe | 650,952 |  |  | 558,952 |  |  | 498,725 |
Latin America | 266,801 |  |  | 191,151 |  |  | 205,862 |
Rest of world | 311,566 |  |  | 252,930 |  |  | 214,304 |
Total net product revenues marketed by the Company | 1,913,603 |  |  | 1,660,733 |  |  | 1,675,754 |
ALDURAZYME net product revenues marketed by Sanofi | 128,422 |  |  | 122,765 |  |  | 130,107 |
Total net product revenues | $ | 2,042,025 |  |  | $ | 1,783,498 |  |  | $ | 1,805,861 |
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
| Years Ended December 31,
| 2022 |  | 2021 |  | 2020
Customer A | 16 | % |  | 18 | % |  | 16 | %
Customer B | 12 | % |  | 14 | % |  | 15 | %
Customer C | 9 | % |  | 10 | % |  | 12 | %
Total | 37 | % |  | 42 | % |  | 43 | %
On a consolidated basis, two customers accounted for 22% and 15% of the Company’s December 31, 2022 accounts receivable balance, respectively, compared to December 31, 2021 when two customers accounted for 28% and 16% of the accounts receivable balance, respectively. As of December 31, 2022 and 2021, the accounts receivable balance for Sanofi included $68.8 million and $67.9 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances. The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the year ended December 31, 2022, 2021, and 2020, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients. While the extent and duration of such effects remain uncertain and difficult to predict, the Company does not expect significant impacts to its operating results and financial condition as a result of the COVID-19 pandemic in future periods. The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, the continuing effects of the COVID-19 pandemic, and supply chain disruptions, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business. Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.
| December 31,
| 2022 |  | 2021
Long-lived assets by geography: |  |  |
United States | $ | 786,509 |  |  | $ | 763,847 |
Ireland | 309,180 |  |  | 304,748 |
Rest of world | 18,633 |  |  | 13,284 |
Total long-lived assets | $ | 1,114,322 |  |  | $ | 1,081,879 |

X
- Definition Concentration risk and segment reporting disclosure. + References No definition available. + Details
Name: | bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock
Namespace Prefix: | bmrn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration